ADA2 and atherosclerosis: Chronopharmacology-based treatment targeting different immune cells (macrophage M0 and T cells gamma delta, plasma cells and monocytes) through different immune-related genes (CAPG, IGSF6, IL18, CECR1, FBP1, MMP7, HLA-DPA1, FTO, CRY1, RORB, and PER1) and immune-related pathways (IFN-γ pathway and PD-1 signalling pathway) might serve as potential therapies for atherosclerosis.